Citations (11)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Anselmo Papa, Eleonora Zaccarelli, Davide Caruso, Patrizia Vici, Pierluigi Benedetti Panici & Federica Tomao. (2016) Targeting angiogenesis in endometrial cancer - new agents for tailored treatments. Expert Opinion on Investigational Drugs 25:1, pages 31-49.
Read now
Read now
Articles from other publishers (10)
Yeh Chen Lee, Stephanie Lheureux, Mansoor Raza Mirza & Amit M. Oza. 2020. Management of Endometrial Cancer. Management of Endometrial Cancer
249
276
.
Suzanne Crumley, Katherine Kurnit, Courtney Hudgens, Bryan Fellman, Michael T. Tetzlaff & Russell Broaddus. (2019) Identification of a subset of microsatellite-stable endometrial carcinoma with high PD-L1 and CD8+ lymphocytes. Modern Pathology 32:3, pages 396-404.
Crossref
Crossref
Raffaele Hellweg, Ashley Mooneyham, Zenas Chang, Mihir Shetty, Edith Emmings, Yoshie Iizuka, Christopher Clark, Timothy Starr, Juan H. Abrahante, Florian Schütz, Gottfried Konecny, Peter Argenta & Martina Bazzaro. (2018) RNA Sequencing of Carboplatin- and Paclitaxel-Resistant Endometrial Cancer Cells Reveals New Stratification Markers and Molecular Targets for Cancer Treatment. Hormones and Cancer 9:5, pages 326-337.
Crossref
Crossref
Tina Fonnes, Hege F. Berg, Therese Bredholt, Per-Henrik D. Edqvist, Kristina Sortland, Anna Berg, Helga B. Salvesen, Lars A. Akslen, Henrica M.J. Werner, Jone Trovik, Ingvild L. Tangen & Camilla Krakstad. (2018) Asparaginase-like protein 1 is an independent prognostic marker in primary endometrial cancer, and is frequently lost in metastatic lesions. Gynecologic Oncology 148:1, pages 197-203.
Crossref
Crossref
Helen J. MacKay, Douglas A. Levine, Victoria L. Bae-Jump, Daphne W. Bell, Jessica N. McAlpine, Alessandro Santin, Gini F. Fleming, David G. Mutch, Kenneth P. Nephew, Nicolas Wentzensen, Paul J. Goodfellow, Oliver Dorigo, Hans W. Nijman, Russell Broaddus & Elise C. Kohn. (2017) Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials. Oncotarget 8:48, pages 84579-84594.
Crossref
Crossref
Yeh C. Lee, Stephanie Lheureux & Amit M. Oza. (2017) Treatment strategies for endometrial cancer: current practice and perspective. Current Opinion in Obstetrics & Gynecology 29:1, pages 47-58.
Crossref
Crossref
Stephanie Lheureux & Amit M. Oza. (2016) Endometrial cancer—targeted therapies myth or reality? Review of current targeted treatments. European Journal of Cancer 59, pages 99-108.
Crossref
Crossref
Yumiko Kiyohara, Kiyoshi Yoshino, Satoshi Kubota, Hiroaki Okuyama, Hiroko Endo, Yutaka Ueda, Toshihiro Kimura, Tadashi Kimura, Shoji Kamiura & Masahiro Inoue. (2016) Drug screening and grouping by sensitivity with a panel of primary cultured cancer spheroids derived from endometrial cancer. Cancer Science 107:4, pages 452-460.
Crossref
Crossref
Victor Rodriguez-Freixinos, Katherine Karakasis & Amit M. Oza. (2016) New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?. Current Oncology Reports 18:4.
Crossref
Crossref
Daliah Tsoref, Stephen Welch, Susie Lau, James Biagi, Katia Tonkin, Lee Ann Martin, Susan Ellard, Prafull Ghatage, Laurie Elit, Helen J. Mackay, Ghassan Allo, Ming-Sound Tsao, Suzanne Kamel-Reid, Elizabeth A. Eisenhauer & Amit M. Oza. (2014) Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer. Gynecologic Oncology 135:2, pages 184-189.
Crossref
Crossref